Development of efficient viral vectors selective for vascular smooth muscle cells.
about
Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectorsImproved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vectorPlectin-1 Targeted AAV Vector for the Molecular Imaging of Pancreatic Cancer.PepBank--a database of peptides based on sequence text mining and public peptide data sources.Ultrasound-mediated delivery of echogenic immunoliposomes to porcine vascular smooth muscle cells in vivoCombinatorial peptide libraries: mining for cell-binding peptides.Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.Neuronal affinity of a C7C loop peptide identified through phage display.In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library.Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerPeptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivoDevelopment of viral vectors for use in cardiovascular gene therapy.Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries.A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases.Current advances and future challenges in Adenoviral vector biology and targetingGene therapy for the prevention of vein graft diseaseNovel vectors for in vivo gene delivery to vascular tissue.Gene therapy to prevent occlusion of venous bypass grafts.Vein graft failure: current clinical practice and potential for gene therapeutics.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.AAV9: over the fence and into the woods . . .Efficient transduction of vascular smooth muscle cells with a translational AAV2.5 vector: a new perspective for in-stent restenosis gene therapy.Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.
P2860
Q24538483-DC98423C-21F7-4A36-8EC1-2272B6FA289AQ24804662-790AF33F-3711-484B-B93C-8BB70D2ED9C6Q30419813-DBE75C6F-CA79-424B-9FD1-4DDCD2ECF0CAQ30444431-762C10ED-A2CB-4940-9040-16D606BD76CFQ30475323-B6C4D8B8-FF04-4A6E-BCB8-9158A668F004Q31144876-AB859A43-DDEF-44C8-8F3B-3266E0E1B52FQ33248410-4E26127C-7064-492B-B7E4-02BAFBD97F02Q33252514-FFB632F3-26CB-46E7-8B6D-6E00DDB2649DQ33327474-3594AE11-C584-4A0A-B3A3-AD7EEC757393Q33555864-8E300ED3-7D68-4C85-8057-33D9B571324FQ33584756-CEE7455C-DD06-4B94-BBC6-B8B66EEF94C3Q33995646-7B57919E-B01A-4509-B68F-AFFD1B5D9FC8Q35260617-8FC4AC49-242A-445F-92BA-46D991707CADQ35649591-4903A0CB-605C-4042-8D52-1FE40A9FFD12Q35904461-A146B54D-809A-4B95-AE48-5FE1488D13FCQ35971198-7EA56203-4225-4EF8-B110-8D4DE4FD42B2Q36006011-751764B9-F6ED-48C6-8369-8C3CF6963A95Q36463004-976BA7E3-21B7-4D63-9AB6-FA882DADE0B8Q36698258-B437752C-BCDB-4215-882B-8507644586B0Q36842711-D2F429CF-DE4D-46CA-A2B8-A12FD8591B89Q37176430-E0B9A2A7-774F-4B91-90E4-15429F15123CQ37997898-B3BE5C53-F53C-46D1-ADC5-AD733805850CQ38614156-431983E5-ECED-4E42-8105-27EF9268FC2DQ40051540-BDB3E90D-2EA5-4EFF-9CA3-A7065E3432B5Q40411990-CD3FFA8D-DAEB-4FB8-8DE6-9E18F4094147Q41880721-D7CD83D2-CBC4-4947-B63F-848E7F6968D7Q42066164-EAB3337B-D2C6-486F-A8E6-EB1BE36EA0C2Q42203239-026F70D7-24F9-4CC1-9937-94B3A7CCD109
P2860
Development of efficient viral vectors selective for vascular smooth muscle cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Development of efficient viral vectors selective for vascular smooth muscle cells.
@ast
Development of efficient viral vectors selective for vascular smooth muscle cells.
@en
type
label
Development of efficient viral vectors selective for vascular smooth muscle cells.
@ast
Development of efficient viral vectors selective for vascular smooth muscle cells.
@en
prefLabel
Development of efficient viral vectors selective for vascular smooth muscle cells.
@ast
Development of efficient viral vectors selective for vascular smooth muscle cells.
@en
P2093
P50
P1433
P1476
Development of efficient viral vectors selective for vascular smooth muscle cells.
@en
P2093
Andrew H Baker
Dan J Von Seggern
Hildegard Büning
Kate L Dishart
Nick J R Brain
P304
P356
10.1016/J.YMTHE.2003.11.006
P577
2004-02-01T00:00:00Z